Skip to main content
. 2023 Mar 13;13(3):512. doi: 10.3390/jpm13030512

Table 2.

Differences between patients with (Group A) and without (Group B) cardiovascular disease (CVD).

Group A (n = 480) Group B (n = 1570) p Value
Age 73.88 ± 8.87 69.79 ± 12.11 <0.0001
Years of smoking 44.03 ± 10.96 41.98 ± 13.45 0.241
Years without smoking 17.08 ± 11.62 16.34 ± 12.83 0.608
Cigarettes per diem 21.11 ± 15.27 20.23 ± 12.57 0.478
Number of previous TURBT 0.53 ± 1.17 0.32 ± 1.02 <0.0001
Number of total TURBT 2.27 ± 1.64 2.18 ± 1.68 0.310
Sex
Male 431 (89.8) 1299 (82.7) <0.0001
Female 49 (10.2) 271 (17.3) <0.0001
Smoker
Yes 120 (25.7) 456 (29.4) <0.0001
No 100 (21.4) 477 (30.8) <0.0001
Ex 247 (52.9) 618 (39.8) <0.0001
Diabetes 157 (32.8) 302 (19.2) <0.0001
Hypertension 353 (73.7) 873 (55.6) <0.0001
Dyslipidemia 148 (34.4) 282 (18) <0.0001
COPD 99 (20.7) 173 (11) <0.0001
Chronic kidney disease 51 (10.7) 92 (5.9) <0.0001
Hepatitis C virus 17 (3.6) 36 (2.3) 0.126
Other cancers 72 (18.8) 254 (22.6) 0.117
Prostate cancer 15 (4.5) 62 (7.8) 0.47
Kidney cancer 11 (3.3) 20 (2.5) 0.462
Upper tract urinary cancer 7 (2.1) 27 (3.4) 0.245
Recurrent tumor 21 (9.3) 109 (10.4) 0.622
Bladder cancer 368 (76.7) 1270 (80.9) 0.048
Grading
G1 68 (14.5) 265 (17.2) 0.024
G2 82 (17.4) 343 (22.2) 0.024
G3 218 (46.4) 661 (42.8) 0.024
Staging
pTa 187 (41.5) 768 (50.5) 0.005
pT1 119 (26.4) 306 (20.1) 0.005
pT2 56 (12.4) 186 (12.2) 0.005
pT4 2 (0.4) 2 (0.1) 0.005
Multifocal 144 (34.1) 400 (29.7) 0.085
Concomitant CIS 22 (5.4) 42 (3.5) 0.087
MIBC 58 (12.5) 188 (12.3) 0.438
Treatment
MMC 39 (8.4) 113 (7.7) 0.764
BCG 68 (14.4) 187 (12.7) 0.764
Cystectomy 11 (2.4) 39 (2.6) 0.764
Re-TURBT 28 (6.1) 87 (5.9) 0.764